SOLASIA/NIPPON-KAYAKU
26.10.2021 12:48:13 CEST | Business Wire | Press release
Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter “this agreement”).
Darinaparsin is a drug candidate under development by Solasia for relapsed or refractory peripheral T-cell lymphoma (PTCL). Solasia filed a new drug application with the Ministry of Health, Labour and Welfare in June 2021 and expects to launch after obtaining approval from the agency in 2022.
Mr. Kazuto Koizumi, Managing Director and Head of Pharmaceuticals Group of Nippon Kayaku, commented as follows:
“Solasia is a specialty pharmaceutical company that excels in development of innovative medicines in the field of oncology in Japan and other Asian countries. Through the early launch of darinaparsin developed by Solasia, we expect to provide a new treatment option for PTCL, and contribute to patients and their family suffering from the disease, as well as to healthcare professionals.”
Mr. Yoshihiro Arai, President and CEO of Solasia, commented as follows:
“Nippon Kayaku is one of Japan's leading pharmaceutical companies with strengths in the field of oncology. We are very pleased to have this opportunity to deliver darinaparsin to nationwide medical institutions providing cancer treatment by utilizing Nippon Kayaku’s extensive experience in oncology and strong sales network, and contribute to the treatment of PTCL.”
Based on this agreement, Solasia and Nippon Kayaku will make further efforts to provide a new treatment option to patient suffering from PTCL, for which no standard treatment has been established to date.
###
About Nippon Kayaku
Nippon Kayaku was founded in 1916 as the first industrial explosives manufacturer in Japan. We have developed products to meet the needs of the time by utilizing, combining and transforming our core technologies in the company’s main areas, explosives, dyes, pharmaceuticals and resins. Nippon Kayaku has contributed to realizing a sustainable society through its four businesses of Functional Chemicals, Pharmaceuticals, Safety Systems, and Agrochemicals.
In the Pharmaceuticals Business, Nippon Kayaku specializes in anticancer drugs and other cancer-related products, handling a range of products from new drugs to biosimilars and generics. It strives to provide trustworthy information crucial for understanding anticancer drugs to medical institutions.
Please visit the company website at https://www.nipponkayaku.co.jp/english/
for more information.
About Solasia
Please visit the company website at https://solasia.co.jp/en/
for more information.
About darinaparsin (SP-02)
Please visit at https://solasia.co.jp/en/pipeline/sp02.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005660/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Belkin Expands Nintendo Switch 2 Accessories Ecosystem With New Charging Grip and Travel Bag4.6.2026 18:00:00 CEST | Press release
Following the January debut of Charging Case Pro, Belkin broadens its gaming portfolio with new ways to power, carry, and play Today, Belkin, a leading consumer electronics brand for 40 years, announced the expansion of its Nintendo Switch 2 accessories ecosystem with the launch of the GamingCharging Grip for Nintendo Switch 2 and Gaming Travel Bag for Nintendo Switch 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604082278/en/ Belkin expands Nintendo Switch 2 accessories ecosystem with new Charging Grip and Travel Bag Following the January debut of the award-winning Charging Case Pro, the new accessories build on Belkin’s growing gaming portfolio, offering players more ways to power, protect and carry their gaming essentials wherever they play. After entering the gaming accessories category in June 2025, Belkin continues to expand its ecosystem with thoughtfully designed products that combine premium materials, practi
DEWA Opens Registration for WETEX 20264.6.2026 17:55:00 CEST | Press release
Dubai Electricity and Water Authority (DEWA) has opened registration for the 28th edition of the Water, Energy, Technology and Environment Exhibition (WETEX), which will take place from 20 to 22 October 2026 at the Dubai World Trade Centre. One of the leading specialised exhibitions of its kind in the world and the largest in the region, WETEX is convened by DEWA under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604642265/en/ DEWA opens registration for WETEX 2026 (Photo: AETOSWire) WETEX covers a wide range of sectors, including energy, water, environment, green development, digital transformation, artificial intelligence (AI), sustainability, decarbonisation, green mobility, green hydroge
LotusFlare’s DNO™ Cloud Powers the Launch of Pi in South Africa4.6.2026 17:49:00 CEST | Press release
LotusFlare, a leading provider of cloud-native, AI-driven digital commerce and monetization platforms for communications service providers (CSPs), today announced its partnership with MTN South Africa to power the launch of its new digital brand, Pi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604149542/en/ At the core of Pi is LotusFlare’s DNO™ Cloud—a fully digital, cloud-native BSS platform that enables delivering a seamless, app-first customer experience at scale. From onboarding to plan management, Pi customers can access 5G mobile, fixed wireless, and travel eSIM services within minutes—without contracts, credit checks, or call centres—through a single, intuitive interface. DNO™ Cloud underpins the entire Pi ecosystem, including front-end digital experiences, product catalog, order management, converged charging, billing, and eSIM orchestration. Deployed on public cloud infrastructure in compliance with South Afr
INRIX Sets the Standard for Predictive and Accurate Parking Intelligence4.6.2026 17:42:00 CEST | Press release
INRIX now has the most parking data in the industry covering 22K cities and 48M spaces INRIX, Inc., a global leader in transportation intelligence, today announced a significantly expanded deployment of its predictive parking and curb intelligence platform, reinforcing its position as the industry’s most comprehensive and decision-grade parking intelligence solution for automotive OEMs, cities, and mobility platforms worldwide. INRIX provides real world coverage based on how parking actually works on-street, off-street, dynamic availability and driver behavior. Others count locations. INRIX understands parking ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604808273/en/ Parking Intelligence for a New Era of Mobility Parking Intelligence for a New Era of Mobility Parking data has traditionally been evaluated based on volume, how many locations are listed, or how many attributes are captured. But as mobility evo
Steady concentration PD with the Carry Life UF system increased ultrafiltration nearly threefold and sodium removal nearly tenfold vs 2.5% dextrose CAPD, while improving glucose efficiency and supporting enhanced fluid management in PD patients4.6.2026 16:45:00 CEST | Press release
Triomed AB today announced positive results from a prospective, multicenter, randomized, crossover study evaluating steady concentration peritoneal dialysis using the Carry Life UF system in adult patients undergoing CAPD. The study demonstrated significant improvements in ultrafiltration, peritoneal sodium removal and glucose ultrafiltration efficiency (ultrafiltration volume in relation to glucose absorption) compared with standard 2.5% dextrose CAPD in the home setting over four weeks. The study results were presented as a Focussed Oral presentation based on a late-breaking clinical trial abstract at the European Renal Association (ERA) Congress in Glasgow, United Kingdom, and simultaneously published in the Journal of the American Society of Nephrology (JASN). In this study, participants received their standard CAPD treatment during the control arm, whereas in the Carry Life UF arm, one daily 2.5% dextrose exchange was replaced by a Carry Life UF treatment three days per week, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom